OncoTherapy Science (4564.T) Osake Kurssi

OncoTherapy Science Inc is primarily active in the biotechnology industry.

The main competitors of OncoTherapy Science Inc in the market include pharmaceutical companies such as Pfizer, Merck & Co., and Novartis.

OncoTherapy Science Inc is a leading biotechnology company specializing in innovative cancer therapies. With a rich history spanning several successful years, OncoTherapy Science Inc has consistently demonstrated its commitment to revolutionizing cancer treatment through cutting-edge research and development. The company has a strong background in targeted therapies, utilizing advanced techniques to understand and combat the complex mechanisms of cancer. OncoTherapy Science Inc prioritizes patient-centric approaches, seeking to improve clinical outcomes and ultimately save lives. Their dedicated team of scientists and researchers are relentlessly working towards discovering breakthrough treatments for various types of cancer, cementing their position as a trusted leader in the field of oncology.

OncoTherapy Science Inc, a leading biotechnology company, has achieved several significant milestones in its journey. The company's dedication to cutting-edge research and innovation has resulted in remarkable achievements. OncoTherapy Science Inc has successfully developed and commercialized groundbreaking therapies for various types of cancers, revolutionizing the treatment landscape. Moreover, the company has received multiple accolades for its exceptional contributions to the field of oncology. OncoTherapy Science Inc's relentless pursuit of excellence has positioned it as a key player in the fight against cancer, making it a trusted name in the industry. With numerous achievements under its belt, OncoTherapy Science Inc continues to pave the way for advancements in cancer treatment.

OncoTherapy Science Inc is primarily present in Japan.

OncoTherapy Science Inc represents values of innovation, integrity, and commitment to advancing cancer treatments. The company's corporate philosophy revolves around conducting groundbreaking research to develop effective therapies for oncology patients. With a focus on precision medicine, OncoTherapy Science Inc aims to deliver personalized and targeted treatments for individuals battling cancer. Their dedication to scientific excellence, collaboration with key stakeholders, and patient-centric approach sets them apart in the field of oncology. OncoTherapy Science Inc's commitment to improving patient outcomes and revolutionizing cancer care aligns with their vision of becoming a global leader in precision oncology.

Nykyisellä valuuttakurssilla OncoTherapy Science-osake noteerataan hintaan 0,10 EUR (18,00 JPY).

OncoTherapy Science-osake (4564.T) on listattuna 3 pörssissä, muun muassa: Tokio (JPX) (4564.T), Frankfurt (30O.F), München (30O.MU).

OncoTherapy Science Inc. is a leading biopharmaceutical company focused on the development of innovative cancer therapies. It offers a comprehensive portfolio of therapeutics and diagnostics to improve the treatment and cure of cancer patients worldwide. The company is divided into different divisions to enable effective development of cancer therapies, including research and development, production, marketing, and distribution of cancer drugs. The research and development department of OncoTherapy Science Inc. consists of a team of scientists and researchers who focus on identifying new therapeutic targets and developing innovative therapeutics. The research department has already made significant advances in the field of personalized medicine. OncoTherapy Science Inc. provides a wide range of products to offer better therapy options for cancer patients, including innovative antibody-based therapeutics, including immunotherapies, cytokines, antibody conjugates, mono- and polyclonal antibodies. The company also works on the development of diagnostics to enhance the effectiveness of therapy options, offering tests and diagnostic instruments that improve the accuracy of diagnosis and help patients choose the best possible therapy option. OncoTherapy Science Inc. also has a production department that utilizes modern technologies and automated production lines. The production facilities are set up according to the latest GMP standards to ensure that the products are of the highest quality and purity and comply with FDA regulations. The company markets and distributes its products worldwide through a network of partners and distributors. It has branches in different countries and collaborations with leading research institutions and universities around the world to support its research and development. In summary, OncoTherapy Science Inc. is a company focused on the research, development, and marketing of cancer therapeutics and diagnostics. It aims to provide better treatment options for cancer patients worldwide and has already made significant progress. With its wide range of innovative products, modern production facility, and strong research and development program, OncoTherapy Science Inc. is a leading company in cancer research and therapy.

liikevaihto OncoTherapy Science on 808,53 M JPY. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

voitto OncoTherapy Science on −910,64 M JPY. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

OncoTherapy Science:n hinta-voitto-suhde (P/E) on tällä hetkellä −7,88. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan OncoTherapy Science-osakkeen arvostusta.

OncoTherapy Science:n hinta-myynti-suhde (P/S) on tällä hetkellä 8,88. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii OncoTherapy Science-osakkeen arvostuskennuslukuna.

OncoTherapy Science:n Eulpool-laatuscore on 3/10.

OncoTherapy Science:n ISIN on JP3202150003. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

OncoTherapy Science:n WKN on 726692. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

OncoTherapy Science:n ticker on 4564.T. Tämä pörssinoteeraus käytetään OncoTherapy Science-osakkeiden kauppaan pörssissä.